Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1995
10/01/1995CA2145960A1 Protein phbp-70
10/01/1995CA2145841A1 Thrombosis agent
09/1995
09/28/1995WO1995025957A1 HUMAN C5a ANTAGONISTS AND AGONISTS
09/28/1995WO1995025956A1 Method of determining the suppressor cell component of the immune status of an individual and means for carrying out the same
09/28/1995WO1995025809A1 Compacted nucleic acids and their delivery to cells
09/28/1995WO1995025808A1 Process for treating eucaryotic cells
09/28/1995WO1995025807A1 Inhibition of arterial smooth muscle cell proliferation
09/28/1995WO1995025806A2 Packaging-deficient lentiviruses
09/28/1995WO1995025805A1 Recombinant viruses coding for a glutamate decarboxylase (gad) activity
09/28/1995WO1995025804A1 Recombinant adenoviruses coding for brain-derived neurotrophic factor (bdnf)
09/28/1995WO1995025803A1 RECOMBINANT ADENOVIRUSES CODING FOR ACIDIC FIBROBLAST GROWTH FACTOR (aFGF)
09/28/1995WO1995025802A1 RECOMBINANT ADENOVIRUSES FOR GLIAL MATURATION FACTOR BETA (GMF-β)
09/28/1995WO1995025796A1 C-terminally truncated cftr genes and proteins
09/28/1995WO1995025795A1 HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
09/28/1995WO1995025786A1 Production of human apolipoprotein a1 in a bacterial expression system
09/28/1995WO1995025749A2 Eating suppressant peptides
09/28/1995WO1995025748A1 Topical fibrinogen complex
09/28/1995WO1995025747A1 Prostaglandin e receptor
09/28/1995WO1995025746A1 Modified polypeptides with increased biological activity
09/28/1995WO1995025745A1 Fucose containing proteoglycan or acid glycan and their pharmace utical use
09/28/1995WO1995025744A1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
09/28/1995WO1995025741A1 Gnrh antagonists
09/28/1995WO1995025740A1 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
09/28/1995WO1995025739A1 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof
09/28/1995WO1995025728A1 Taxane derivatives with antitumor activity
09/28/1995WO1995025543A1 Methods and compositions useful for inhibition of angiogenesis
09/28/1995WO1995025542A1 Composition including a recombinant plasmid, and uses thereof as a vaccine and drug
09/28/1995WO1995025539A1 Novel remedy for respiratory-tract viral disease
09/28/1995WO1995025537A1 Drug for relieving side effects caused by immunosuppressants
09/28/1995WO1995025536A1 Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
09/28/1995WO1995025535A1 Thyroxin-binding proteins
09/28/1995WO1995025534A1 Stabilized composition for oral administration of peptides
09/28/1995WO1995025533A1 PROTEASOME REGULATION OF NF-λB ACTIVITY
09/28/1995WO1995025532A1 Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
09/28/1995WO1995025531A1 Means for treating auto-immune diseases and method of treatment
09/28/1995WO1995025530A1 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof
09/28/1995WO1995025529A1 New methods of use of acth analogs
09/28/1995WO1995025528A1 Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection
09/28/1995WO1995025519A1 Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide disulfide derivatives
09/28/1995WO1995025513A1 Zinc compound and cyclodextrine for treatment of gastric disorders
09/28/1995WO1995025508A1 Treating cyclosporine-induced nephrotoxicity
09/28/1995WO1995025505A1 Hydrophobic drug delivery systems
09/28/1995WO1995025429A1 Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
09/28/1995WO1995023860A3 KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID β-PROTEIN PRECURSOR INHIBITOR
09/28/1995WO1995023855A3 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells
09/28/1995WO1995022612A3 Genes and genetic elements associated with sensitivity to platinum-based drugs
09/28/1995WO1995020666A3 Transgenic non-human mammals with progressive neurologic disease
09/28/1995DE4438838C1 DNA-Sequenzen für Matrix-Metallproteasen, ihre Herstellung und ihre Verwendung DNA sequences for matrix metalloproteases, their preparation and their use
09/28/1995DE19510551A1 Oral insulin prepns resistant to proteolytic enzymes
09/28/1995CA2186231A1 Prostaglandin e receptor
09/28/1995CA2186111A1 Novel remedy for respiratory-tract viral disease
09/28/1995CA2186035A1 Thyroxin-binding proteins
09/28/1995CA2186016A1 Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection
09/28/1995CA2186006A1 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof
09/28/1995CA2186005A1 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof
09/28/1995CA2185892A1 Means for treating auto-immune diseases and method of treatment
09/28/1995CA2185795A1 Method of determining the suppressor cell component of the immune status of an individual and means for carrying out the same
09/28/1995CA2185710A1 Gnrh antagonists
09/28/1995CA2185450A1 Eating suppressant peptides
09/28/1995CA2184409A1 Recombinant adenoviruses coding for acidic fibroblast growth factor (afgf)
09/28/1995CA2184408A1 Recombinant adenoviruses for glial maturation factor beta (gmf-.beta.)
09/28/1995CA2184200A1 Recombinant viruses, preparation and use in genic therapy
09/28/1995CA2183647A1 Process for treating eucaryotic cells
09/28/1995CA2162997A1 Topical fibrinogen complex
09/28/1995CA2162147A1 Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
09/27/1995EP0674178A2 Cyclosporin immunoassay
09/27/1995EP0674004A1 MSRV1 virus and pathogenic and/or infections agent MSRV2 linked to multiple sclerosis, their nucleic components and their applications
09/27/1995EP0673936A1 Antithrombotic agents
09/27/1995EP0673653A1 Biologically active agent having immunomodulating properties, method for its obtaining and pharmaceutical preparation based on it
09/27/1995EP0673652A1 Biologically active agent having immunomodulating properties, method for its obtaining and pharmaceutical preparation based on it
09/27/1995EP0673643A1 Cosmetic composition containing an association of superoxide dismutase and porphyrine
09/27/1995EP0673431A1 Gene therapy for cystic fibrosis
09/27/1995EP0673430A1 Nucleotide sequence for treating cancer and infection
09/27/1995EP0673426A1 Platelet-activating factor acetylhydrolase
09/27/1995EP0673421A1 Allergenic proteins and peptides from johnson grass pollen
09/27/1995EP0673420A1 Mammalian receptors for interleukin-10 (il-10)
09/27/1995EP0673419A1 Stably transfected cell lines expressing gaba-a receptors
09/27/1995EP0673417A1 LIGAND BINDING VARIABLE DOMAIN (V-MIN) COMPRISING A FRAMEWORK REGION WITH A CYCLICALLY PERMUTED CENTRAL $g(b)-BARREL
09/27/1995EP0673390A1 Delta-like gene expressed in neuroendocrine tumors
09/27/1995EP0673388A1 Double chain peptide compounds having hemoregulatory activity
09/27/1995EP0673385A1 Mammalian gap-43 compositions and methods of use
09/27/1995EP0673384A1 Polypeptides useful for treating inflammatory disorders
09/27/1995EP0673257A1 Low toxicity interleukin-2 analogues for use in immunotherapy
09/27/1995EP0673256A1 Suppression of myeloid cells
09/27/1995EP0673255A1 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
09/27/1995EP0673254A1 6-position modified decapeptide lhrh antagonists
09/27/1995EP0673241A1 A free radical quenching liposomal composition
09/27/1995EP0673234A1 Tissue protective and regenerative compositions
09/27/1995EP0673199A1 Stabilized lanthionine bacteriocin compositions
09/27/1995EP0573554B1 Use of at least one purified peptide obtainable by hydrolysis of casein and having opioid activity as active principle in the manufacture of a cosmetic composition
09/27/1995EP0462189B1 Combination therapy for treatment of estrogen sensitive diseases
09/27/1995EP0440734B1 Diet composition to improve survival of patients during sepsis
09/27/1995EP0348490B1 Treatment of type 2 diabetes mellitus
09/27/1995EP0261225B1 Lectin complex and method and probe for making same
09/27/1995CN1108955A The use of compositions for combating tumour diseases
09/27/1995CN1108930A Soft gelatin capsule manufacture
09/26/1995US5453492 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
09/26/1995US5453491 Purified and comprising specified amino acid sequences; therapy for autoimmune disorders and eosinophilia
09/26/1995US5453489 Specific amino acid sequences; bind directly to fibronectin, reduces matrix assembly without affecting binding to cells; antitumor/wound healing agents
09/26/1995US5453488 Amino-substituted heterocycles as renin inhibitors
1 ... 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 2842 2843 2844 2845 ... 3163